Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Public ClinicalTrials.gov record NCT03391466. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Study identification
- NCT ID
- NCT03391466
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 359 participants
Conditions and interventions
Interventions
- Axicabtagene Ciloleucel Biological
- Platinum-containing Salvage Chemotherapy Drug
- Cyclophosphamide Drug
- Fludarabine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 25, 2018 (Actual)
- Primary completion
- Mar 18, 2021 (Actual)
- Completion
- Nov 25, 2024 (Actual)
- Last update posted
- Dec 1, 2025
2018 – 2024
United States locations
- U.S. sites
- 30
- U.S. states
- 20
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Mayo Clinic Hospital | Phoenix | Arizona | 85054 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| UCLA | Santa Monica | California | 90404 | — |
| Stanford Cancer Institute | Stanford | California | 94305 | — |
| University of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 12902 | — |
| Northwestern University | Chicago | Illinois | 60612 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| University of Iowa Hospitals and Clinincs | Iowa City | Iowa | 52242 | — |
| The University of Kansas Cancer Center | Kansas City | Kansas | 66160 | — |
| University of Maryland, Greenbaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic, Patient Location | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine | St Louis | Missouri | 63130 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15213 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Henry-Joyce Cancer Center | Nashville | Tennessee | 37232 | — |
| The University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03391466, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2025 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03391466 live on ClinicalTrials.gov.